1. Home
  2. MIRM vs CAKE Comparison

MIRM vs CAKE Comparison

Compare MIRM & CAKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CAKE
  • Stock Information
  • Founded
  • MIRM 2018
  • CAKE 1972
  • Country
  • MIRM United States
  • CAKE United States
  • Employees
  • MIRM N/A
  • CAKE N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CAKE Restaurants
  • Sector
  • MIRM Health Care
  • CAKE Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • CAKE Nasdaq
  • Market Cap
  • MIRM 3.3B
  • CAKE 2.8B
  • IPO Year
  • MIRM 2019
  • CAKE 1992
  • Fundamental
  • Price
  • MIRM $67.93
  • CAKE $62.99
  • Analyst Decision
  • MIRM Strong Buy
  • CAKE Hold
  • Analyst Count
  • MIRM 9
  • CAKE 14
  • Target Price
  • MIRM $73.89
  • CAKE $61.14
  • AVG Volume (30 Days)
  • MIRM 661.2K
  • CAKE 1.7M
  • Earning Date
  • MIRM 08-06-2025
  • CAKE 07-29-2025
  • Dividend Yield
  • MIRM N/A
  • CAKE 1.72%
  • EPS Growth
  • MIRM N/A
  • CAKE 35.29
  • EPS
  • MIRM N/A
  • CAKE 3.24
  • Revenue
  • MIRM $429,161,000.00
  • CAKE $3,669,456,000.00
  • Revenue This Year
  • MIRM $36.76
  • CAKE $7.13
  • Revenue Next Year
  • MIRM $17.48
  • CAKE $6.10
  • P/E Ratio
  • MIRM N/A
  • CAKE $19.44
  • Revenue Growth
  • MIRM 62.33
  • CAKE 4.77
  • 52 Week Low
  • MIRM $36.86
  • CAKE $35.40
  • 52 Week High
  • MIRM $69.00
  • CAKE $69.70
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 82.95
  • CAKE 50.32
  • Support Level
  • MIRM $50.25
  • CAKE $60.69
  • Resistance Level
  • MIRM $67.45
  • CAKE $64.87
  • Average True Range (ATR)
  • MIRM 2.89
  • CAKE 2.14
  • MACD
  • MIRM 1.38
  • CAKE -0.16
  • Stochastic Oscillator
  • MIRM 94.29
  • CAKE 33.14

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CAKE Cheesecake Factory Incorporated (The)

Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.

Share on Social Networks: